Tetra Biopharmaceutical company, a front runner in the research, discovery, and development of drugs derived from cannabinoids, has revealed the evaluation of its experimental novel medication ARDS-003, in a virally infected in-vitro animal cell model, in collaborative research conducted by George Mason University and Targeted Pharmaceuticals. ARDS-003 is a novel patent-protected treatment for hyper-inflammatory disorders, like those that have been observed in Covid-19 infections and septicemia (blood infection).
Tetra Biopharma has signed an agreement with Targeted Pharmaceuticals for further research on its key drug product ARDS-003. Initial research on HIV conducted by utilizing HU-308 chemical, an API (Active Pharmaceutical Ingredient) present in ARDS-003, revealed that when HU-308 is administered in conjunction with the typical antiviral medication to treat HIV (Human Immunodeficiency Virus), viral replication is considerably reduced.
To put it another way, it treats the infection far more effectively than a single antiviral medication. These findings indicate that ARDS-003 has an antiviral activity in humans in addition to immunomodulatory characteristics.
Extracellular vesicles are involved in the immune response of the body against viral infections, as well as in post-infection complications such as neurodegenerative disorders. They are involved in triggering or suppressing immune responses against the virus by incorporating and disseminating both viral and host components, through a variety of mechanisms.
According to the research, Extracellular vesicles (EVs) have been linked to SARS-COV-2 infection. Evs have been implicated in the transmission of viral receptors to various cells of the body rendering them more vulnerable to SARS-COV-2 infection. Moreover, viral infections are a common cause of sepsis, as per the Sepsis Alliance.
Dr. Guy Chamberland stated, “Our partnership with Targeted is allowing us to learn more about the therapeutic potential of our proprietary drug ARDS-003. We believe this partnership will lead to new market opportunities for both corporations as we leverage our cannabinoid inhalation intellectual property as well as that of the ARDS-003 drug.”
